Prem Prakash Kushwaha and Shashank Kumar
Central University of Punjab, India
Posters & Accepted Abstracts: J Cancer Sci Ther
Statement of the problem: Cancer drug resistance reduces the effect of the drug(s) in cancer cells. Triple-negative
breast cancer (TNBC) is an aggressive disease with a poor therapy outcome. Drug resistance and self-renewal
properties of stem cells make it an attractive target for anticancer drug discovery. ABC transporter and stemness
markers are positively involved in stem cell drug resistance. Nowadays natural remedies are of interest due to lesser
side effects and cost-effective. Taken together, there is an urgent need to identify novel natural anti-drug resistant and
anticancer agents against TNBC stem cells.
Methodology & Theoretical Orientation: Different scientific literature database were used to prepare the list of
phytochemicals present in Bulbine spp. Molecular docking and simulation approach was used to identify the ABC
transporter inhibitor from the enlisted phytochemicals. Literature shows that the enlisted phytochemicals are soluble
in the polar solvent. Thus, we prepared the methanolic (polar) extract of Bulbine spp. Anti-drug resistance and
anticancer activity of the extract was examined by using MTT, drug efflux, and colony formation assay. Further, the
therapeutic potential of the extract was studied in terms of apoptosis induction and reduction in stemness markers
(Oct4, Sox2, Nanog, and Myc) at the transcriptional level.
Findings: In silico study revealed potent phytochemical showing better binding affinity with ABC transporter in
comparison to standard inhibitors. Extract inhibited the mammosphere formation and reduced colony formation
in TNBC cells. Treatment showed reduced drug efflux activity, down-regulated stem cell markers and induced
apoptosis in the cells.
Conclusion & Significance:> Present in silico and in vitro study suggest that Bulbine spp. phytochemicals have antidrug
resistance and anti-cancer stem cell potential. The phytochemicals may act as the lead candidate for drug
development against triple negative breast cancer stem cells.
E-mail: prembiochembch@gmail.com
Cancer Science & Therapy received 5282 citations as per Google Scholar report